Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Receivables - Other: 2020-2023

  • Mereo BioPharma Group's Receivables - Other was N/A to $1.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.9 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2023, which is N/A change from last year.
  • Mereo BioPharma Group's Receivables - Other amounted to $1.9 million in Q4 2023, which was up 53.31% from $1.3 million recorded in Q2 2022.
  • In the past 5 years, Mereo BioPharma Group's Receivables - Other registered a high of $2.3 million during Q2 2020, and its lowest value of $1.3 million during Q2 2022.
  • For the 3-year period, Mereo BioPharma Group's Receivables - Other averaged around $1.6 million, with its median value being $1.7 million (2021).
  • Examining YoY changes over the last 5 years, Mereo BioPharma Group's Receivables - Other showed a top increase of 42.58% in 2021 and a maximum decrease of 36.85% in 2021.
  • Quarterly analysis of 4 years shows Mereo BioPharma Group's Receivables - Other stood at $1.3 million in 2020, then spiked by 42.58% to $1.9 million in 2021, then dropped by 11.65% to $1.3 million in 2022, then reached $1.9 million in 2023.
  • Its last three reported values are $1.9 million in Q4 2023, $1.3 million for Q2 2022, and $1.9 million during Q4 2021.